DekaBank Deutsche Girozentrale purchased a new stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,000 shares of the company's stock, valued at approximately $532,000.

Several other large investors have also made changes to their positions in VTYX. Legal & General Group Plc lifted its stake in shares of Ventyx Biosciences by 152.3% during the second quarter. Legal & General Group Plc now owns 2,422 shares of the company's stock valued at $30,000 after acquiring an additional 1,462 shares during the period. High Net Worth Advisory Group LLC lifted its stake in Ventyx Biosciences by 100.0% in the third quarter. High Net Worth Advisory Group LLC now owns 1,000 shares of the company's stock valued at $35,000 after buying an additional 500 shares during the period. Virtus ETF Advisers LLC acquired a new position in Ventyx Biosciences in the second quarter valued at about $97,000. American International Group Inc. lifted its stake in Ventyx Biosciences by 102.3% in the second quarter. American International Group Inc. now owns 10,490 shares of the company's stock valued at $128,000 after buying an additional 5,305 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. acquired a new position in Ventyx Biosciences in the second quarter valued at about $132,000. Institutional investors and hedge funds own 95.57% of the company's stock.

Ventyx Biosciences Stock Performance

Shares of Ventyx Biosciences stock opened at $41.46 on Friday. Ventyx Biosciences, Inc. has a 1 year low of $9.50 and a 1 year high of $43.81. The business has a 50-day moving average of $31.56 and a two-hundred day moving average of $27.52.

Analysts Set New Price Targets

VTYX has been the topic of several analyst reports. Morgan Stanley initiated coverage on Ventyx Biosciences in a research note on Thursday, November 17th. They issued an "overweight" rating and a $45.00 target price on the stock. The Goldman Sachs Group initiated coverage on Ventyx Biosciences in a research note on Monday, December 19th. They issued a "buy" rating and a $50.00 target price on the stock. Oppenheimer increased their target price on Ventyx Biosciences from $55.00 to $60.00 and gave the company an "outperform" rating in a research note on Friday. Finally, Evercore ISI increased their target price on Ventyx Biosciences from $50.00 to $65.00 in a research note on Thursday. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Ventyx Biosciences presently has an average rating of "Buy" and a consensus price target of $50.67.

Insider Buying and Selling

In related news, major shareholder Nsv Partners Iii Lp sold 143,228 shares of the stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $29.01, for a total transaction of $4,155,044.28. Following the completion of the transaction, the insider now directly owns 16,745,365 shares in the company, valued at $485,783,038.65. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, major shareholder Nsv Partners Iii Lp sold 143,228 shares of the stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $29.01, for a total transaction of $4,155,044.28. Following the completion of the transaction, the insider now directly owns 16,745,365 shares in the company, valued at $485,783,038.65. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director William Richard White sold 33,353 shares of the firm's stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $35.10, for a total value of $1,170,690.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,206,646 shares of company stock worth $36,781,043. 49.10% of the stock is owned by corporate insiders.

Ventyx Biosciences Company Profile

(Get Rating)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Read More

• Get a free copy of the StockNews.com research report on Ventyx Biosciences (VTYX)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.